Dima Main Page - DIMA Biotechnology

Technology Platform

Membrane Protein Expression & Purification

DIMA uses HEK293 mammalian cell expression system to produce many druggable proteins especially membrane proteins. This will not only ensure the authentic posttranslational modifications from mammalian cells, but also have a high chance of obtaining proteins in good solubility and correct folding under standard buffer system. In addition to active ECD fusion proteins, DIMA now offers 5 platforms for the full-length multipass transmembrane proteins including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc Proteins.

Learn More

Single B Cell mAb Development Platform

Unlike traditional monoclonal antibody (mAb) production platforms that rely on hybridoma fusion, our Single B Cell mAb Development Platform eliminates the need for hybridoma fusion. Instead, we can directly isolate positive B cells from the peripheral blood of immunized animals following immunization. These B cells are then used to sequence the gene of the monoclonal antibody. With this approach, we can obtain over 1,000 positive B cell clones from a single immunized animal, resulting in a significantly higher overall positive clone rate compared to the traditional hybridoma platform.

Learn More

DiLibrary™ Antibody Engineering Platform

The DiLibrary™ platform provides one-step antibody engineering, including humanization, chimerization, and affinity maturation, along with developability assessments, all utilizing a mammalian cell display system. Delivering results in just 48 days, this platform ensures high affinity retention and a high degree of humanization, all at a cost-effective range of $20K–$40K.

Learn More